India News

India’s Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients

FILE PHOTO: A guard walks inside the office of Sun Pharmaceutical Industries Ltd in Mumbai, India, November 13, 2018. REUTERS/Francis Mascarenhas

BENGALURU – Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.

“Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany,” the company said in a statement

The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.


MAY 29, 2020

Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Anil D’SilvaOur Standards:The Thomson Reuters Trust Principles.

Categories: India News

Tagged as: , ,

Leave a Reply